|
新井田 達雄
Department School of Medicine(Yachiyo Medical Center), School of Medicine Position Professor (Fixed Term) |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer. |
| Journal | Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：17917530/02507005 |
| Volume, Issue, Page | 39(9),pp.4729-4736 |
| Author and coauthor | KURAMOCHI Hidekazu, NAKAJIMA Go, HAYASHI Kazuhiko, ARAIDA Tatsuo, YAMAMOTO Masakazu |
| Publication date | 2019/09 |
| Summary | BACKGROUND/AIM:Amphiregulin (AREG) and epiregulin (EREG) mRNA expression levels are predictors of response to anti-EGFR antibody therapy. Left-sided colon cancer is more sensitive to anti-EGFR antibodies than right-sided, although the mechanism is unclear. The aim of this study was to determine the relationship between AREG, EREG mRNA expression levels and tumor location as well as the efficacy of anti-EGFR antibody agents.MATERIALS AND METHODS:Real-time PCR was used to assess AREG and EREG mRNA expression in metastatic colorectal cancer (CRC) samples from 153 patients.RESULTS:Among KRASwt samples, high AREG expression (AREGHigh) was significantly more common in left-sided tumors than in right-sided. Among patients who received anti-EGFR antibody, response rates were significantly higher in AREGHigh than in AREGLow In the left-sided tumor group, overall survival was significantly longer in patients with high EREG levels than with low levels, whereas the right-sided tumor group showed no survival difference between them.CONCLUSION:AREG and EREG mRNA expression levels in left-sided CRC were higher than in right-sided tumors. This may help explain why left-sided CRC is more responsive to anti-EGFR antibodies. |
| DOI | 10.21873/anticanres.13655 |
| PMID | 31519572 |